Efficacy and Safety of Dual-target CAR-T Therapy for Newly Diagnosed High-Risk Multiple Myeloma
The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, Spain, from June 13 to 16, 2024. At this EHA conference, a study (S200) by Professors Juan Du and Jing Lu from Shanghai Changzheng Hospital was selected for an oral presentation. This study explored the efficacy and safety of GC012F in the first-line treatment of newly diagnosed high-risk multiple myeloma patients eligible for transplantation. To discuss the study and the treatment of multiple myeloma, "Oncology Frontier - Hematology Frontier" conducted an interview with Professor Jing Lu.